|
Home
>
Newsletters
>
FDAnews Drug Daily Bulletin
> Teva Rebuffed in Patent Cases Over Antibiotic, Herpes Drug
FDAnews Drug Daily Bulletin
Nov. 6, 2009
| Vol.
6 No.
217
Teva Rebuffed in Patent Cases Over Antibiotic, Herpes Drug
Two federal courts have issued rulings against
Teva Pharmaceuticals USA in cases involving its proposed generic versions of Alcon’s antibiotic
Vigamox and Novartis Pharmaceuticals’ herpes treatment Famvir. Judge Sue Robinson of the U.S. District Court for the District of Delaware ruled Teva
failed to prove that a patent covering Vigamox (moxifloxcin HCl), which is used to treat conjunctivitis, is invalid. Separately, U.S. District Court for
the District of New Jersey Judge Dennis Cavanaugh refused to grant Teva’s motion to dismiss two Novartis subsidiaries from the case involving the
herpes drug Famvir (famciclovir).
Generic Line |
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews
All rights reserved. Do not duplicate or redistribute in any form.